| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
Division of Hematology and Oncology [B. G. R., P. E., Q. P., S. D. M.], Departments of Internal Medicine [G. J. B.], Radiology [H. K. H., T. C.], Human Genetics [G. J. B.], and University of Michigan Comprehensive Cancer Center [B. G. R., R. L. D., S. D. M.], University of Michigan, Ann Arbor, Michigan 48109-0948
Purpose: Tetrathiomolybdate (TM), a copper-lowering agent, has been shown in preclinical murine tumor models to be antiangiogenic. We evaluated the antitumor activity of TM in patients with advanced kidney cancer in a Phase II trial.
Experimental Design: Fifteen patients with advanced kidney cancer were eligible to participate in this trial. TM was initiated p.o. at 40 mg three times a day with meals and 60 mg at bedtime to deplete copper. A target serum ceruloplasmin (CP) level of 5–15 mg/dl was defined as copper depletion. Doses of TM were reduced for grade 3–4 toxicity and to maintain a CP level in the target range. Once copper depletion was attained, patients underwent baseline tumor measurements and then again every 12 weeks for response assessment. Patients not exhibiting progressive disease at 12 weeks after copper depletion continued on treatment. Serum levels of Interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were assayed pretreatment and at various time points on treatment. Dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI) was performed on selected patients in an attempt to assess changes in tumor vascularity.
Results: All of the patients rapidly became copper depleted. Thirteen patients were evaluable for response. No patient had a complete response or PR. Four patients (31%) had stable disease for at least 6 months during copper depletion (median, 34.5 weeks). TM was well tolerated, with dose reductions most commonly occurring for grade 3–4 granulocytopenia of short duration not associated with febrile episodes. Serum levels of IL-6, IL-8, VEGF, and bFGF did not correlate with clinical activity. Serial DCE-MRI was performed only in four patients, and a decrease in vascularity seemed to correlate with necrosis of a tumor mass associated with tumor growth.
Conclusions: TM is well tolerated and consistently depletes copper as measured by the serum CP level. Clinical activity was limited to stable disease for a median of 34.5 weeks in this Phase II trial in patients with advanced kidney cancer. Serum levels of proangiogenic factors IL-6, IL-8, VEGF, and bFGF may correlate with copper depletion but not with disease stability in this small cohort. TM may have a role in the treatment of kidney cancer in combination with other antiangiogenic therapies.
This article has been cited by other articles:
|
|
 |
|
  J. C. Juarez, M. Manuia, M. E. Burnett, O. Betancourt, B. Boivin, D. E. Shaw, N. K. Tonks, A. P. Mazar, and F. Donate Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling PNAS, May 20, 2008; 105(20): 7147 - 7152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Itoh, H. W. Kim, O. Nakagawa, K. Ozumi, S. M. Lessner, H. Aoki, K. Akram, R. D. McKinney, M. Ushio-Fukai, and T. Fukai Novel Role of Antioxidant-1 (Atox1) as a Copper-dependent Transcription Factor Involved in Cell Proliferation J. Biol. Chem., April 4, 2008; 283(14): 9157 - 9167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Du, G. Filiz, A. Caragounis, P. J. Crouch, and A. R. White Clioquinol Promotes Cancer Cell Toxicity through Tumor Necrosis Factor {alpha} Release from Macrophages J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 360 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chen, Q. C. Cui, H. Yang, R. A. Barrea, F. H. Sarkar, S. Sheng, B. Yan, G. P. V. Reddy, and Q. P. Dou Clioquinol, a Therapeutic Agent for Alzheimer's Disease, Has Proteasome-Inhibitory, Androgen Receptor-Suppressing, Apoptosis-Inducing, and Antitumor Activities in Human Prostate Cancer Cells and Xenografts Cancer Res., February 15, 2007; 67(4): 1636 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Finney, S. Mandava, L. Ursos, W. Zhang, D. Rodi, S. Vogt, D. Legnini, J. Maser, F. Ikpatt, O. I. Olopade, et al. X-ray fluorescence microscopy reveals large-scale relocalization and extracellular translocation of cellular copper during angiogenesis PNAS, February 13, 2007; 104(7): 2247 - 2252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yu, J. Wong, D. B. Lovejoy, D. S. Kalinowski, and D. R. Richardson Chelators at the Cancer Coalface: Desferrioxamine to Triapine and Beyond Clin. Cancer Res., December 1, 2006; 12(23): 6876 - 6883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mandinov, K. L. Moodie, A. Mandinova, Z. Zhuang, F. Redican, D. Baklanov, V. Lindner, T. Maciag, M. Simons, and E. D. de Muinck Inhibition of in-stent restenosis by oral copper chelation in porcine coronary arteries Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2692 - H2697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chen, Q. C. Cui, H. Yang, and Q. P. Dou Disulfiram, a Clinically Used Anti-Alcoholism Drug and Copper-Binding Agent, Induces Apoptotic Cell Death in Breast Cancer Cultures and Xenografts via Inhibition of the Proteasome Activity Cancer Res., November 1, 2006; 66(21): 10425 - 10433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Juarez, O. Betancourt Jr., S. R. Pirie-Shepherd, X. Guan, M. L. Price, D. E. Shaw, A. P. Mazar, and F. Donate Copper Binding by Tetrathiomolybdate Attenuates Angiogenesis and Tumor Cell Proliferation through the Inhibition of Superoxide Dismutase 1. Clin. Cancer Res., August 15, 2006; 12(16): 4974 - 4982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Payne, B. Fogelgren, A. R. Hess, E. A. Seftor, E. L. Wiley, S. F.T. Fong, K. Csiszar, M. J.C. Hendrix, and D. A. Kirschmann Lysyl Oxidase Regulates Breast Cancer Cell Migration and Adhesion through a Hydrogen Peroxide-Mediated Mechanism Cancer Res., December 15, 2005; 65(24): 11429 - 11436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Brem, S. A. Grossman, K. A. Carson, P. New, S. Phuphanich, J. B. Alavi, T. Mikkelsen, J. D. Fisher, and for the New Approaches to Brain Tumor Therapy CNS Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma Neuro-oncol, July 1, 2005; 7(3): 246 - 253. [Abstract] [PDF]
|
|
|
|
|
|
W.-Q. Ding, B. Liu, J. L. Vaught, H. Yamauchi, and S. E. Lind Anticancer Activity of the Antibiotic Clioquinol Cancer Res., April 15, 2005; 65(8): 3389 - 3395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. N. Teknos, M. Islam, D. A. Arenberg, Q. Pan, S. L. Carskadon, A. M. Abarbanell, B. Marcus, S. Paul, C. D. Vandenberg, M. Carron, et al. The Effect of Tetrathiomolybdate on Cytokine Expression, Angiogenesis, and Tumor Growth in Squamous Cell Carcinoma of the Head and Neck Arch Otolaryngol Head Neck Surg, March 1, 2005; 131(3): 204 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. K. Askari, R. Dick, M. Mao, and G. J. Brewer Tetrathiomolybdate Therapy Protects Against Concanavalin A and Carbon Tetrachloride Hepatic Damage in Mice Experimental Biology and Medicine, September 1, 2004; 229(8): 857 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Wahl, T. L. Moser, and S. V. Pizzo Angiostatin and Anti-angiogenic Therapy in Human Disease Recent Prog. Horm. Res., January 1, 2004; 59(1): 73 - 104. [Abstract] [Full Text]
|
|
|
|
 |
|
 Q. Pan, L. W. Bao, and S. D. Merajver Tetrathiomolybdate Inhibits Angiogenesis and Metastasis Through Suppression of the NF{kappa}B Signaling Cascade Mol. Cancer Res., August 1, 2003; 1(10): 701 - 706. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
